US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Ready Capital Corp

25.04

0.0000

Volume:- -

Turnover:- -

Market Cap:4.11B

PE:-12.77

High:25.04

Open:25.04

Low:25.04

Close:25.04

52wk High:26.87

52wk Low:23.97

Shares:164.33M

Float Shares:164.33M

Volume Ratio:- -

T/O Rate:- -

Dividend:1.44

Dividend Rate:5.74%

EPS(TTM):-1.9610

ROE:-13.30%

ROA:-2.87%

PB:2.47

PE(LYR):- -

Loading ...

Overview Company News Filings

Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Salim Syed Initiates Buy on Arcus, Citing Casdatifan’s Foundational RCC Potential and Diversified Late-Stage Pipeline Ahead of 2026 Inflection Data

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Trevi Therapeutics to Participate in Upcoming August Conferences

Analyst Maintains Buy Rating and Unchanged $40 Price Target on Encouraging Darlifarnib Combination Data in Advanced RCC

Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Is Arcus Biosciences (RCUS) Using the ROSETTA Trial Tie-Up to Quietly Reframe Its RCC Strategy?

Simply Wall St.

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference

Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026

Press Release: Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating

Press Release: Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Trevi Therapeutics to Participate in Upcoming Events

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/RCC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCC\",,,,,undefined,":{"symbol":"RCC","market":"US","secType":"STK","nameCN":"Ready Capital Corp","latestPrice":25.04,"timestamp":1783627200000,"preClose":25.04,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":164327000,"shares":164327000,"eps":-1.961,"marketStatus":"Not Yet Opened","change":0,"latestTime":"07-09 16:00:00 EDT","open":25.04,"high":25.04,"low":25.04,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.961,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":25.04,"dividendRate":0.05741,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCC\",,,,,undefined,":{"symbol":"RCC","floatShares":164327000,"roa":"-2.87%","roe":"-13.30%","lyrEps":0,"shares":164327000,"dividePrice":1.437535,"high":25.04,"amplitude":0,"preClose":25.04,"low":25.04,"week52Low":23.97,"pbRate":"2.47","psRate":"-38.40","week52High":26.87,"institutionHeld":0,"latestPrice":25.04,"eps":-1.961,"divideRate":0.05741,"volume":0,"delay":0,"ttmEps":-1.961,"open":25.04,"prevYearClose":25.05,"prevWeekClose":25.04,"prevMonthClose":24.92,"prevQuarterClose":25.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCC\",params:#limit:5,,,undefined,":[{"date":"2026-02-26","symbol":"RCC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772139600000,"name":null,"time":"Post-Mkt","dateTimestamp":1772082000000,"actualEps":null},{"market":"US","date":"2026-02-17","symbol":"RCC","reason":null,"defaultRemindTime":1771338600000,"announcedDate":"2026-01-26","type":"delisting","dateTimestamp":1771304400000},{"date":"2026-01-15","symbol":"RCC","amount":0.3594,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-15","defaultRemindTime":1768487400000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-30","payableDate":"2026-01-15","currency":"USD","dateTimestamp":1768453200000,"payDate":"2026-01-30"},{"date":"2025-10-15","symbol":"RCC","amount":0.359375,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-15","defaultRemindTime":1760535000000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-30","payableDate":"2025-10-15","currency":"USD","dateTimestamp":1760500800000,"payDate":"2025-10-30"},{"date":"2025-07-15","symbol":"RCC","amount":0.35938,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-15","defaultRemindTime":1752586200000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-30","payableDate":"2025-07-15","currency":"USD","dateTimestamp":1752552000000,"payDate":"2025-07-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCC\",market:\"US\",,,undefined,":[{"executeDate":"2021-04-14","recordDate":"2021-04-15","paymentDate":"2021-04-30","value":0.3194444,"currency":"USD"},{"executeDate":"2021-07-14","recordDate":"2021-07-15","paymentDate":"2021-07-30","value":0.359375,"currency":"USD"},{"executeDate":"2021-10-14","recordDate":"2021-10-15","paymentDate":"2021-10-30","value":0.359375,"currency":"USD"},{"executeDate":"2022-01-13","recordDate":"2022-01-14","paymentDate":"2022-01-30","value":0.359375,"currency":"USD"},{"executeDate":"2022-04-13","recordDate":"2022-04-14","paymentDate":"2022-04-30","value":0.359375,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RCC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.875,"sell":0.125,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.875,"analysts":8,"updateTime":1766120400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659641571","title":"Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2659641571","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659641571?lang=en_us&edition=fundamental","pubTime":"2026-08-14 03:35","pubTimestamp":1786649725,"startTime":"0","endTime":"0","summary":"In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on Trevi Therapeutics, with a price target of $28.00. De...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/trevi-therapeutics-initiated-at-buy-on-clean-late-stage-execution-de-risked-ipf-cough-and-rcc-pipelines-and-solid-cash-position-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/trevi-therapeutics-initiated-at-buy-on-clean-late-stage-execution-de-risked-ipf-cough-and-rcc-pipelines-and-solid-cash-position-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","RCC","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661430","title":"Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661430","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661430?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Ini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340705/0/en/Trevi-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","HYLG","BMED","BK4007","IDNA","BK4539","RCC","LENZ","MEDX","NVIB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657658746","title":"Salim Syed Initiates Buy on Arcus, Citing Casdatifan’s Foundational RCC Potential and Diversified Late-Stage Pipeline Ahead of 2026 Inflection Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2657658746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657658746?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:57","pubTimestamp":1786028222,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Salim Syed has maintained their bullish stance on RCUS stock, giving a Buy rating today. Salim Syed has given his Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/salim-syed-initiates-buy-on-arcus-citing-casdatifans-foundational-rcc-potential-and-diversified-late-stage-pipeline-ahead-of-2026-inflection-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/salim-syed-initiates-buy-on-arcus-citing-casdatifans-foundational-rcc-potential-and-diversified-late-stage-pipeline-ahead-of-2026-inflection-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655385448","title":"Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655385448","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655385448?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:05","pubTimestamp":1785441900,"startTime":"0","endTime":"0","summary":"Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., July  30, 2026  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3336431/0/en/Trevi-Therapeutics-to-Report-Second-Quarter-2026-Financial-Results-and-Provide-a-Corporate-Update-on-August-6-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4007","BK4539","RCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654004327","title":"Trevi Therapeutics to Participate in Upcoming August Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2654004327","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654004327?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:30","pubTimestamp":1785238200,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., July  28, 2026  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334133/0/en/Trevi-Therapeutics-to-Participate-in-Upcoming-August-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4007","BK4139","RCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654041628","title":"Analyst Maintains Buy Rating and Unchanged $40 Price Target on Encouraging Darlifarnib Combination Data in Advanced RCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2654041628","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654041628?lang=en_us&edition=fundamental","pubTime":"2026-07-27 23:55","pubTimestamp":1785167716,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kura Oncology. The associated price target remains the same with $4...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-rating-and-unchanged-40-price-target-on-encouraging-darlifarnib-combination-data-in-advanced-rcc-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-rating-and-unchanged-40-price-target-on-encouraging-darlifarnib-combination-data-in-advanced-rcc-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RCC","AEIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653818637","title":"Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2653818637","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653818637?lang=en_us&edition=fundamental","pubTime":"2026-07-22 07:10","pubTimestamp":1784675400,"startTime":"0","endTime":"0","summary":"SHANGHAI, July  21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3331033/0/en/Junshi-Biosciences-Announces-Acceptance-of-the-Supplemental-Application-for-Toripalimab-plus-Chemotherapy-as-Perioperative-Treatment-for-Resectable-Stage-NSCLC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFS","LU2487616109.SGD","L","BK4588","LU0210528500.USD","LU1861220207.SGD","RCC","LU1861217088.USD","LU0053666078.USD","LU1791807156.HKD","BK4006","LU2360107671.USD","BK4107","HCC","LU1668664300.SGD","LU0106831901.USD","BK4585","BK4166","COAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651170527","title":"Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170527","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651170527?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:02","pubTimestamp":1784026920,"startTime":"0","endTime":"0","summary":"– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-nave, advanced ccRCC patients – – Updated data expected to support darlif","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326716/35186/en/Kura-Oncology-to-Present-First-Long-Term-Follow-Up-Data-Further-Supporting-Darlifarnib-s-Potential-to-Enhance-VEGFR-Targeted-Therapy-in-Renal-Cell-Carcinoma-at-KCRS-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KURA","MEDX","LU0300736492.USD","IDNA","GDOC","BK4505","LU0300736062.USD","LU0053671581.USD","FTI","LU0054578231.USD","LU1804176565.USD","PXJ","IE00BD6J9T35.USD","BK4179","RCC","IEZ","LU2417539215.USD","OIH","LU2456880835.USD","LU2265009873.SGD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644743002","title":"Trevi Therapeutics Announces Upcoming June and July Event Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2644743002","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644743002?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:30","pubTimestamp":1781695800,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., June  17, 2026  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.(Nasdaq: TRVI),a clinical-stage biopharmaceutical company developing the investigationaltherapyHaduvio(oral nalbuphine ER)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313329/0/en/Trevi-Therapeutics-Announces-Upcoming-June-and-July-Event-Schedule.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","RCC","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642239898","title":"Is Arcus Biosciences (RCUS) Using the ROSETTA Trial Tie-Up to Quietly Reframe Its RCC Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2642239898","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642239898?lang=en_us&edition=fundamental","pubTime":"2026-06-12 01:23","pubTimestamp":1781198636,"startTime":"0","endTime":"0","summary":"On 3 June 2026, Bristol Myers Squibb announced a clinical trial collaboration and supply agreement under which Arcus Biosciences will provide its investigational HIF-2a inhibitor casdatifan for new combination arms in the Phase 1/2 ROSETTA RCC-208 study in advanced renal cell carcinoma, while both parties retain rights to their respective assets in this non-exclusive deal.\nThis collaboration highlights growing external interest in casdatifan as a potential component of combination regimens,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rcus/arcus-biosciences/news/is-arcus-biosciences-rcus-using-the-rosetta-trial-tie-up-to","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rcus/arcus-biosciences/news/is-arcus-biosciences-rcus-using-the-rosetta-trial-tie-up-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RCC","RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951862","title":"NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951862","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951862?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315200,"startTime":"0","endTime":"0","summary":"55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg)Favorable safety and tolerability i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304283/0/en/NextCure-Presents-Positive-SIM0505-Phase-1-Dose-Escalation-Data-in-Patients-with-Gynecologic-Cancers-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4213","KOL","ORR","BK4007","PR","PROC","BK4080","BK4231","RCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638522563","title":"Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2638522563","media":"GlobeNewswire","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638522563?lang=en_us&edition=fundamental","pubTime":"2026-05-27 09:18","pubTimestamp":1779844680,"startTime":"0","endTime":"0","summary":"SHANGHAI, May  26, 2026  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301588/0/en/Junshi-Biosciences-Announces-Primary-Endpoints-Met-in-Final-Analysis-of-Phase-3-Study-for-Perioperative-Toripalimab-plus-Chemotherapy-for-Resectable-Stage-II-III-NSCLC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","BK4006","BK4134","LU0210528500.USD","SSI","LU2487616109.SGD","LU2360107671.USD","DFS","III","BK4107","BK4166","LU1861217088.USD","HCC","LU1861220207.SGD","BK4585","BK4588","LU1791807156.HKD","LU0053666078.USD","L","RCC","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637211382","title":"Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2637211382","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637211382?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:28","pubTimestamp":1779359280,"startTime":"0","endTime":"0","summary":"SHANGHAI, May  21, 2026  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299131/0/en/Junshi-Biosciences-Announces-Approval-of-Toripalimab-NDA-for-the-1st-line-treatment-of-HER2-Expressing-Urothelial-Carcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCC","ORR","HCC","HR","BK4225","BK4203","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633924297","title":"Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633924297","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633924297?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011500,"startTime":"0","endTime":"0","summary":"Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and contin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288254/0/en/Trevi-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ATS","BK4585","LENZ","BK4139","RCC","BK4539","BK4161","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632722666","title":"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2632722666","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632722666?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:05","pubTimestamp":1777579500,"startTime":"0","endTime":"0","summary":"Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3285477/0/en/Trevi-Therapeutics-Announces-Oral-Presentation-and-Multiple-Posters-Accepted-at-the-American-Thoracic-Society-ATS-2026-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATS","BK4007","RCC","AFG","BK4117","FAS","BK4107","BK4161","LENZ","BK4539","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631053324","title":"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631053324","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631053324?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:05","pubTimestamp":1777406700,"startTime":"0","endTime":"0","summary":"Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., April  28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/28/3283172/0/en/Trevi-Therapeutics-to-Report-First-Quarter-2026-Financial-Results-and-Provide-a-Corporate-Update-on-May-5-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4007","RCC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629759907","title":"Press Release: Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2629759907","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629759907?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:05","pubTimestamp":1776715500,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., April 20, 2026  -- Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis , non-IPF interstitial lung disease , and refractory chronic cough , today announced the closing of its previously announced underwritten public offering of 13,340,000 shares of its common stock at a public offering price of $13.00 per share, which includes 1,740,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the public offering at the public offering price, less underwriting discounts and commissions. The total proceeds of the public offering were approximately $173 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering were sold by Trevi.Morgan Stanley, Leerink Partners, Cantor, and Sti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","LENZ","BK4604","LU0234570918.USD","LU1668664300.SGD","LU2133065610.SGD","BK4139","LU0320765646.SGD","LU2089284900.SGD","LU1732799900.SGD","BK4007","LU2111349929.HKD","03160","LU1244550494.USD","LU0098860793.USD","LU0314104364.USD","LU0106261372.USD","LU1162221912.USD","LU0267386448.USD","RCC","TM","BK4539","LU0006306889.USD","BK4555","BK4581","LU0225283273.USD","LU1363072403.SGD","BK4534","LU2023251221.USD","LU0106831901.USD","LU0158827948.USD","BK4585","LU1791710582.SGD","LU2347655156.SGD","LU0912757837.SGD","LU2271345857.HKD","LU0158827781.USD","LU0557290698.USD","LU0882574139.USD","IE00BKVL7J92.USD","LU1548497426.USD","TRVI","LU0795875086.SGD","BK4588","LU1720051017.SGD","LU1732800096.USD","LU1989772840.SGD","BK4127","IE00BZ1G4Q59.USD","LU0795875169.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628784843","title":"Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2628784843","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628784843?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:05","pubTimestamp":1776456334,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Charles Zhu maintained a Buy rating on Kura Oncology today and set a price target of $28.00. Charles Zhu has given his Buy ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kura-oncology-compelling-darlifarnib-cabozantinib-data-in-post-io-rcc-support-continued-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kura-oncology-compelling-darlifarnib-cabozantinib-data-in-post-io-rcc-support-continued-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KURA","POST","RCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628246704","title":"Press Release: Trevi Therapeutics Announces Proposed Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2628246704","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628246704?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:08","pubTimestamp":1776370080,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., April 16, 2026  -- Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis , non-IPF interstitial lung disease , and refractory chronic cough , today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. All of the shares in the offering are being offered by Trevi. In addition, Trevi expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550221.USD","LU0225283273.USD","LU0106831901.USD","LU0158827948.USD","BK4585","LU0106261372.USD","LU0557290698.USD","BK4534","LU0912757837.SGD","LU1791710582.SGD","LU2023251221.USD","LU2133065610.SGD","BK4127","03160","BK4516","LU2357305700.SGD","LU0314104364.USD","LU0882574139.USD","RCC","LU1244550494.USD","BK4007","BK4504","IE00BKVL7J92.USD","LU2028103732.USD","LU1668664300.SGD","LU1732800096.USD","LU1791710400.SGD","BK4555","LU1244550577.SGD","LU1989772923.USD","BK4581","LU1162221912.USD","LU0098860793.USD","TM","BK4588","LU0795875086.SGD","LU1363072403.SGD","LU1989772840.SGD","LU0971096721.USD","LU2347655156.SGD","LU2271345857.HKD","LU0267386448.USD","BK4539","BK4139","LENZ","LU0158827781.USD","LU2089284900.SGD","TRVI","LU2111349929.HKD","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624518320","title":"Trevi Therapeutics to Participate in Upcoming Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2624518320","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624518320?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:30","pubTimestamp":1775043000,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., April  01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/01/3266503/0/en/Trevi-Therapeutics-to-Participate-in-Upcoming-Events.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","RCC","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}